Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A12 | P48065 | 5/20 | 0.43 |
| ▸ | SLC6A11 | P48066 | 5/20 | 0.43 |
| ▸ | SLC6A13 | Q9NSD5 | 5/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.35 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.34 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.34 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.34 |
| ▸ | CDC25A | P30304 | 1/20 | 0.34 |
| ▸ | SLC6A1 | P30531 | 2/20 | 0.33 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.33 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.33 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.33 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21510225 | 1.00 | SLC6A12 (0.43) | SLC6A12SLC6A11SLC6A13USP2EPHX1 | |
| SCHEMBL19513333 | 0.95 | SLC6A12 (0.43) | SLC6A12SLC6A11SLC6A13USP2EPHX1 | |
| SCHEMBL3276937 | 0.95 | SLC6A12 (0.43) | SLC6A12SLC6A11SLC6A13USP2EPHX1 | |
| SCHEMBL9764134 | 0.93 | SLC6A12 (0.41) | SLC6A12SLC6A11SLC6A13USP2EPHX1 | |
| SCHEMBL4634265 | 0.83 | ANPEP (0.37) | SLC6A12SLC6A11SLC6A13USP2EPHX1 | |
| SCHEMBL11051978 | 0.83 | SLC6A12 (0.52) | SLC6A12SLC6A11SLC6A13AKR1C4AKR1C3 | |
| SCHEMBL14571159 | 0.82 | EPHX1 (0.40) | EPHX1L3MBTL1CA1CA2CA4 | |
| SCHEMBL29211200 | 0.81 | SLC1A2 (0.36) | SLC6A12SLC6A11SLC6A13CDC25ACYP1A2 | |
| SCHEMBL10489468 | 0.79 | EPHX1 (0.41) | USP2EPHX1L3MBTL1CA1CA2 | |
| SCHEMBL8342817 | 0.78 | FOLH1 (0.37) | USP2EPHX1CYP1A2L3MBTL1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| CN-108473518-B | Bisphosphonic acid compounds | 株式会社富士药品 | 2021-07-06 | — | — | CN | disclosed |
| US-10689408-B2 | Bisphosphonic acid compound | FUJIYAKUHIN CO., LTD. (JP) | 2020-06-23 | — | — | US | disclosed |
| US-20190002482-A1 | NOVEL BISPHOSPHONIC ACID COMPOUND | FUJIYAKUHIN CO., LTD. (JP) | 2019-01-03 | — | — | US | disclosed |
| EP-3409679-A1 | NOVEL BISPHOSPHONIC ACID COMPOUND | Fuji Yakuhin Co., Ltd. (JP) | 2018-12-05 | — | — | EP | disclosed |
| CN-108473518-A | New double phosphinic acid compounds | 株式会社富士药品 | 2018-08-31 | — | — | CN | disclosed |
| EP-2610248-B1 | METHOD FOR PRODUCING PHENYL-SUBSTITUTED HETEROCYCLIC DERIVATIVE BY MEANS OF COUPLING METHOD USING A PALLADIUM COMPOUND | TEIJIN PHARMA LTD (JP) | 2016-06-08 | — | — | EP | disclosed |
| CN-103068807-B | By using the preparation method of phenyl substituted heterocycle derivative of coupling process of palladium compound | TEIJIN PHARMA LTD. (JP) | 2016-05-25 | — | — | CN | disclosed |
| US-8952174-B2 | Process for producing phenyl-substituted heterocyclic derivative through coupling using transition metal catalyst | TEIJIN PHARMA LIMITED (JP) | 2015-02-10 | — | — | US | disclosed |
| CN-102333765-B | Process for producing phenyl-substituted heterocyclic derivative through coupling using transition metal catalyst | TEIJIN PHARMA LTD | 2015-01-14 | — | — | CN | disclosed |
| US-8916714-B2 | Method for producing phenyl-substituted heterocyclic derivative by means of coupling method using palladium compound | TEIJIN PHARMA LIMITED (JP) | 2014-12-23 | — | — | US | disclosed |
| EP-2610248-A1 | METHOD FOR PRODUCING PHENYL-SUBSTITUTED HETEROCYCLIC DERIVATIVE BY MEANS OF COUPLING METHOD USING A PALLADIUM COMPOUND | Teijin Pharma Limited (JP) | 2013-07-03 | — | — | EP | disclosed |
| US-20130158272-A1 | METHOD FOR PRODUCING PHENYL-SUBSTITUTED HETEROCYCLIC DERIVATIVE BY MEANS OF COUPLING METHOD USING PALLADIUM COMPOUND | TEIJIN PHARMA LIMITED (JP) | 2013-06-20 | — | — | US | disclosed |
| CN-103068807-A | Method for producing phenyl-substituted heterocyclic derivative by means of coupling method using a palladium compound | TEIJIN PHARMA LTD | 2013-04-24 | — | — | CN | disclosed |
| EP-2404908-A1 | PROCESS FOR PRODUCING PHENYL-SUBSTITUTED HETEROCYCLIC DERIVATIVE THROUGH COUPLING USING TRANSITION METAL CATALYST | Teijin Pharma Limited (JP) | 2012-01-11 | — | — | EP | disclosed |
| US-20110313169-A1 | PROCESS FOR PRODUCING PHENYL-SUBSTITUTED HETEROCYCLIC DERIVATIVE THROUGH COUPLING USING TRANSITION METAL CATALYST | TEIJIN PHARMA LIMITED (JP) | 2011-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110313169-A1 | PROCESS FOR PRODUCING PHENYL-SUBSTITUTED HETEROCYCLIC DERIVATIVE THROUGH COUPLING USING TRANSITION METAL CATALYST | XDH, PAH, HPRT1 | SLC6A12 1390/4885SLC6A11 2241/4885SLC6A13 2061/4885 |
| US-10689408-B2 | Bisphosphonic acid compound | SOST, PTH1R, BMP2 | SLC6A12 859/4885SLC6A11 124/4885SLC6A13 220/4885 |
| US-20130158272-A1 | METHOD FOR PRODUCING PHENYL-SUBSTITUTED HETEROCYCLIC DERIVATIVE BY MEANS OF COUPLING METHOD USING PALLADIUM COMPOUND | XDH, AOC1, PAH | SLC6A12 2117/4885SLC6A11 2271/4885SLC6A13 2648/4885 |
| US-20190002482-A1 | NOVEL BISPHOSPHONIC ACID COMPOUND | SOST, PTH1R, BMP2 | SLC6A12 866/4885SLC6A11 135/4885SLC6A13 229/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.